Formycon AG
FYB | F
Overview
Corporate Details
- ISIN(s):
- DE000A1EWVY8
- LEI:
- 39120005TZ76GQOY8Z19
- Country:
- Germany
- Address:
- Fraunhoferstraße 15, 82152 Planegg
- Website:
- https://www.formycon.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval. We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-31 13:49 |
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.4 KB | |
| 2025-07-30 06:30 |
Earnings Release
Formycon invites to conference call on 2025 half-year results and announces par…
|
English | 13.6 KB | |
| 2025-07-16 07:20 |
Report Publication Announcement
|
English | 3.9 KB | |
| 2025-07-10 06:30 |
Regulatory News Service
Formycon successfully completes patient enrollment for the clinical developmen…
|
English | 15.2 KB | |
| 2025-07-01 13:15 |
Regulatory News Service
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcentaTM (ran…
|
English | 14.8 KB | |
| 2025-06-27 15:51 |
Capital/Financing Update
Formycon increases bond volume following oversubscription Bond 2025/2029 with …
|
English | 14.9 KB | |
| 2025-06-26 06:30 |
Regulatory News Service
Teva becomes secondary commercialization partner for Formycon's Stelara biosimi…
|
English | 15.6 KB | |
| 2025-06-25 06:30 |
Regulatory News Service
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization part…
|
English | 17.0 KB | |
| 2025-06-24 19:50 |
Capital/Financing Update
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscriptio…
|
English | 19.6 KB | |
| 2025-06-20 09:00 |
Capital/Financing Update
Formycon bond 2025/2029: Public subscription now also possible via Deutsche Bor…
|
English | 19.8 KB | |
| 2025-06-18 16:43 |
Declaration of Voting Results & Voting Rights Announcements
Ordinary Annual General Meeting of Formycon AG approves all proposed resolution…
|
English | 12.9 KB | |
| 2025-06-18 06:25 |
Capital/Financing Update
Formycon AG: Subscription period for 2025/2029 corporate bond has started
|
English | 20.5 KB | |
| 2025-06-17 08:01 |
Capital/Financing Update
Formycon plans public corporate bond issuance to support next growth phase with…
|
English | 21.3 KB | |
| 2025-06-05 06:30 |
Regulatory News Service
Lucentis biosimilar FYB201/Ranivisio (ranibizumab) approved in Brazil
|
English | 14.5 KB | |
| 2025-05-27 14:30 |
Regulatory News Service
Formycon and Fresenius Kabi announce the commercial launch of FYB202/OtulfiTM, …
|
English | 15.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-21 | Seidl, Dr. Andreas | Board | Buy | None | 4,800.00 EUR |
| 2024-04-29 | Mikulcik, Dr. Marc | Close relation | Buy | None | 48,000.00 EUR |
| 2024-04-24 | Glombitza, Dr. Stefan | Board | Buy | None | 97,444.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
BSF ENTERPRISE PLC | United Kingdom | BSFA | |
|
Can-Fite BioPharma Ltd. | Israel | CANF | |
|
Cantargia | Sweden | CANTA | |
|
Captor Therapeutics S.A. | Poland | CTX | |
|
Carbiotix AB | Sweden | CRBX | |
|
Cellectis | France | ALCLS | |
|
CELLULAR GOODS PLC | United Kingdom | CBX | |
|
Celyad Oncology SA | Belgium | CYAD | |
|
Cereno Scientific AB | Sweden | CRNO | |
|
Cessatech A/S | Denmark | CESSA |